- Joined
- Mar 6, 2009
- Messages
- 26,497
ACT1 PEPTIDE via systemic injection
ACT1 is a systemic peptide that potentiates wound healing when given via IP injection. In animals, IP injection is used predominantly in veterinary medicine and animal testing for the administration of systemic drugs and fluids due to the ease of administration compared with other parenteral methods. This link shows ACT1 PEPTIDE to be effective at wound healing when given systemically.
**broken link removed**
ACT1 - Gap Closure and Wound Width in IP Findings:
For the in vivo effects of intraperitoneal ACT 1 as measured by a rat wound healing model, full-thickness 8mm punch biopsy wounds were made on the dorsal surface of rats (2). ACT 1 (60 micrograms in 300 microliters normal saline) was injected intraperitoneally on injury date and every other day thereafter. Likewise, identical amounts of normal saline (NS) were injected intraperitoneally to control animals. Intraperitoneal injection of ACT 1 between days 4-7 resulted in a 42% (+/- 9%) and an 18% decrease in gap length and wound width, respectively, when compared to NS alone.
Conclusion:
Intrapertoneal ACT 1 appears to significantly decrease the gap size and wound width of artificial wounds in a rat wound-healing model system. These findings lend support to the high diffusibility of ACT 1 in tissues.
ACT1 is a systemic peptide that potentiates wound healing when given via IP injection. In animals, IP injection is used predominantly in veterinary medicine and animal testing for the administration of systemic drugs and fluids due to the ease of administration compared with other parenteral methods. This link shows ACT1 PEPTIDE to be effective at wound healing when given systemically.
**broken link removed**
ACT1 - Gap Closure and Wound Width in IP Findings:
For the in vivo effects of intraperitoneal ACT 1 as measured by a rat wound healing model, full-thickness 8mm punch biopsy wounds were made on the dorsal surface of rats (2). ACT 1 (60 micrograms in 300 microliters normal saline) was injected intraperitoneally on injury date and every other day thereafter. Likewise, identical amounts of normal saline (NS) were injected intraperitoneally to control animals. Intraperitoneal injection of ACT 1 between days 4-7 resulted in a 42% (+/- 9%) and an 18% decrease in gap length and wound width, respectively, when compared to NS alone.
Conclusion:
Intrapertoneal ACT 1 appears to significantly decrease the gap size and wound width of artificial wounds in a rat wound-healing model system. These findings lend support to the high diffusibility of ACT 1 in tissues.
Last edited: